Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Roku’s Business Is on Fire. Buy ROKU Stock Before It Flies to $500.

By Luke Lango, InvestorPlace Senior Investment Analyst
Roku's strong Q1 numbers underscore that recent weakness in ROKU stock is completely unwarranted.

Axon Crushed Earnings. Next Stop for AXON Stock? $200.

By Luke Lango, InvestorPlace Senior Investment Analyst
The Axon growth narrative continues to fire on all cylinders, underscoring why AXON stock is a buy-and-hold situation.

Beyond Meat’s Earnings Sucked. Why BYND Stock Is Still a Buy.

By Luke Lango, InvestorPlace Senior Investment Analyst
Beyond Meat had a bad first three months of 2021, but things will get better from here, so buy BYND stock on the dip.

Why Zomedica Stock Isn’t Worth Buying Right Now

By Ian Cooper, InvestorPlace Contributor
If Truforma truly is a game-changer, there’s hope the company could grab part of a potential $10.5 billion animal diagnostics market.

These 3 Investments Are Better Options Than QuantumScape

By Will Ashworth, InvestorPlace Contributor
QuantumScape lost 18% in April. QS stock is now down 64% year-to-date through May 4. Is there a better way to play this falling knife?

There Is a Silver Lining With AMC’s Q1 2021 Results

By Will Ashworth, InvestorPlace Contributor
AMC Entertainment reported Q1 2021 results. The good news if you own AMC stock is that next year’s comps will look tremendous by comparison.

7 Cyclical Stocks To Consider if the Economic Recovery Story Pans Out

By Josh Enomoto, InvestorPlace Contributor
If you believe that Joe Biden's administration can truly build back better, these cyclical stocks may deliver some impressive gains.

Don’t Look Now, but Bionano Genomics May Be a Buy

By Chris Tyler, InvestorPlace Contributor
Bionano Genomics has lost a lot of supporters in recent months and some never came to the rescue, but a lifeline has been thrown to BNGO stock.

WKHS Stock Is Still Scorched Earth After USPS Debacle

By Faizan Farooque, InvestorPlace Contributor
In many ways, WKHS is a classic example of over-promising and under-delivering.

Clover Health Faces Hurdles to Reach New Highs

By Tezcan Gecgil, InvestorPlace Contributor
CLOV stock cannot return to its early glory unless investors are convinced that its technology platform gives it a solid competitive moat.

Is It Game On or Game Over for Naked Brands?

By Chris Markoch, InvestorPlace Contributor
NAKD stock may still be a good trade. But to be more than that the company needs to generate a lot of revenue in a very competitive market. 

7 Reddit Penny Stocks With Interesting Plans

By Thomas Niel, InvestorPlace Contributor
So, which Reddit penny stocks with ambitious plans could pay off down the road? Consider these seven high-risk, high-potential plays as ones where risk/return leans in your favor:

Forget Sundial Growers, Buy This Calgary Company Instead

By Will Ashworth, InvestorPlace Contributor
Sundial Growers has a market capitalization of $1.73 billion. Based in Calgary, Alberta, SNDL stock isn't the best cannabis stock in the town.

Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance

By Chris Lau, InvestorPlace Contributor
OGCN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators.

Palantir CEO’s Billion-Dollar Payday Is Hardly Worth It

By Will Ashworth, InvestorPlace Contributor
Palantir filed its 2020 proxy on April 29. CEO Alex Karp made $1.1 billion in PLTR stock options. Will he be worth it? Peter Thiel hopes so.  

Ocugen Stock Is a Risky Proposition Despite Its High Valuation

By Divya Premkumar, InvestorPlace Contributor
OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges.

Is Too Much Risk Priced Into Social Capital Hedosophia V Now?

By Chris MacDonald, InvestorPlace Contributor
Investors in IPOE stock are betting on the long-term growth potential of SoFi in the context of heightened risks being priced in today.

3 Reasons To Maintain Caution With Plug Power Stock

By Josh Enomoto, InvestorPlace Contributor
While PLUG stock is at a hefty discount relative to its remarkable peak valuation, don’t be too sure that lighting will strike twice.

Salesforce: The Latest Leg Down

By Dana Blankenhorn, InvestorPlace Contributor
Salesforce.com is still growing at 20% per year and is still making money. But the market is no longer valuing that as highly as it did, with reopening and infrastructure plays drawing more interest.
Load More Articles